Key result
Torasemide reduced single supraventricular extrasystoles to 277.8 per day compared to 1089.9 with furosemide and prevented significant worsening of atrial depolarization parameters.
Why the study?
Does torasemide improve signal-averaged ECG parameters and reduce supraventricular arrhythmias compared to furosemide in patients with coronary heart disease and chronic heart failure?
RCT (n=107)
Random numbers
No
Does torasemide improve signal-averaged ECG parameters and reduce supraventricular arrhythmias compared to furosemide in patients with coronary heart disease and chronic heart failure?
Torasemide demonstrates a more favorable electrophysiological profile than furosemide in patients with heart failure, potentially reducing the risk of supraventricular arrhythmias.
Answers are grounded in this paper and cite their sources.
Torasemide may be preferred over furosemide to limit supraventricular ectopy in HF; extends loop-diuretic comparisons to atrial electrophysiology endpoints.
Aim. To study the signal-averaged ECG (SA-ECG) parameters of atrial complex and supraventricular arrhythmias (SVA) in patients with coronary heart disease (CHD) and chronic heart failure (CHF), treated with diuretics (D) torasemide and furosemide. Material and methods. The study included 107 patients with CHD and CHF. All participants underwent 24-hour ECG monitoring and the registration of SA-ECG atrial complex parameters. In total, 52 patients received furosemide, and 55 were administered torasemide. Results. In both groups, D therapy was associated with some increase in the duration of filtered P and LAS5, as well as a decrease in RMS20. These changes were more pronounced in the furosemide-treated patients. Torasemide demonstrated better effects on the SVA dynamics, which manifested in the decreased numbers of single, paired, and grouped SV extrasystoles. Conclusion. In CHD and CHF patients, the disturbed atrial depolarisation was manifested in negative dynamics of SA-ECG atrial complex parameters. Torasemide therapy did not affect the atrial complex parameters and also reduced SVA incidence, which made torasemide a medication of choice for patients with CHD and CHF.
No takes yet. Share an insight, caveat, or question.
Шугушев et al. (2011) conducted an RCT in Coronary heart disease and chronic heart failure (n=107). Torasemide vs. Furosemide 20-60 mg/day was evaluated on Single supraventricular extrasystoles per day (p=<0.05). Torasemide reduced single supraventricular extrasystoles to 277.8 per day compared to 1089.9 with furosemide and prevented significant worsening of atrial depolarization parameters.
Synapse has enriched 10 related papers. Consider them for comparative context: